Search - tctmd.com

Displaying 1 - 20 of 186

Sort: Relevancy | Date

News Conference News ACC 2025

Cardiologists Plot Next Moves After New Board Rejected

Yael L. Maxwell

April 11, 2025

News Conference News ACC 2025

EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes

L.A. McKeown

April 07, 2025

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

News Conference News ACC 2025

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

L.A. McKeown

March 31, 2025

News Conference News ACC 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Michael O'Riordan

March 31, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

Presentation ACC 2025

The MIGHTy-Heart Randomized Clinical Trial

Presenter: Ruth Masterson Creber

March 30, 2025

Presentation ACC 2025

FAIR-HF2 Trial: Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality

Presenter: Stefan D. Anker

March 30, 2025

Presentation ACC 2025

Liberal Fluid Intake versus Fluid Restriction in Chronic Heart Failure: The FRESH-UP Study

Presenter: Roland R. Van Kimmenade

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Dapagliflozin after Transcatheter Aortic Valve Implantation

Presenter: Sergio Raposeiras-Roubin

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Caitlin E. Cox

April 15, 2024

News Conference News ACC 2024

Vaping Linked to Higher Risk of HFpEF, NIH Data Show

L.A. McKeown

April 12, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

Presentation ACC 2024

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

Presenter: Martin S. Maron

April 08, 2024

Presentation ACC 2024

A Selective Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiomyopathy

Presenter: James L. Januzzi Jr

April 08, 2024

Advertisement

Cardiologists Plot Next Moves After New Board Rejected

EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

The MIGHTy-Heart Randomized Clinical Trial

FAIR-HF2 Trial: Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality

Liberal Fluid Intake versus Fluid Restriction in Chronic Heart Failure: The FRESH-UP Study

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Dapagliflozin after Transcatheter Aortic Valve Implantation

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

WARRIOR: No Clear Answers on How to Best Treat INOCA

What’s Going to Be Hot at ACC 2025?

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Vaping Linked to Higher Risk of HFpEF, NIH Data Show

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

A Selective Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content